In this manuscript, Yao et al. present solid evidence to show that MnMYL3 may serve as a receptor for NNV via macropinocytosis. This manuscript is valuable for understanding the molecular mechanisms ...

Tevogen Bio’s platform shows potential, but financial challenges persist. Read why TVGN stock remains a "Hold" due to funding ...

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and ...

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate ...

Imagine a world where diabetes could be treated with a simple pill that essentially reprograms your body to produce insulin ...

Diabetes researchers and bioinformaticians from the Icahn School of Medicine at Mount Sinai have developed a new ...

Upstream Bio's verekitug targets severe asthma, CRSwNP, and COPD, with promising early phase 2 data expected in 2025 and 2026 ...

Researchers identified a new receptor, neuropilin-1 (NRP1), which collaborates with a known receptor to regulate pain ...

Study published in Science says a single hemagglutinin mutation, similar to one seen in a Canadian case, could make H5N1 ...

Smile! The horror box office hit of the fall is coming to spook you on the small screen soon. Smile 2, the pop star-centric sequel to Parker Finn's 2022 feature, is one of the rare film follow-ups ...

When is the Ark 2 release date? Ever since the Ark 2 announcement at The Game Awards 2020, we’ve been looking forward to learning more about the upcoming dinosaur-themed survival game.